Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving total-body irradiation and chemotherapy, such as fludarabine and thiotepa,
before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It
also helps stop the patient's immune system from rejecting the donor's stem cells. When
healthy stem cells from a donor are infused into the patient, they may help the patient's
bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells.
Giving antithymocyte globulin and removing the T cells from the donor cells before transplant
may stop this from happening.
PURPOSE: This phase II trial is studying how well a donor stem cell transplant works in
treating patients with myeloid cancer or other disease.
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Collaborator:
Center for International Blood and Marrow Transplant Research